AnaptysBio Management

Management criteria checks 3/4

AnaptysBio's CEO is Dan Faga, appointed in Mar 2022, has a tenure of 2.67 years. total yearly compensation is $7.46M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth $9.68M. The average tenure of the management team and the board of directors is 2.7 years and 3.7 years respectively.

Key information

Dan Faga

Chief executive officer

US$7.5m

Total compensation

CEO salary percentage	8.6%
CEO tenure	2.7yrs
CEO ownership	1.3%
Management average tenure	2.7yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan Faga's remuneration changed compared to AnaptysBio's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$166m
Jun 30 2024	n/a	n/a	-US$170m
Mar 31 2024	n/a	n/a	-US$163m
Dec 31 2023	US$7m	US$641k	-US$164m
Sep 30 2023	n/a	n/a	-US$148m
Jun 30 2023	n/a	n/a	-US$144m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$25m	US$474k	-US$129m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$108m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$310k	n/a	-US$58m

Compensation vs Market: Dan's total compensation ($USD7.46M) is above average for companies of similar size in the UK market ($USD1.45M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan Faga (44 yo)

2.7yrs

Tenure

US$7,461,920

Compensation

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel Faga	President	2.7yrs	US$7.46m	1.32% $ 9.7m
Eric Loumeau	Chief Legal Officer	6.3yrs	US$2.26m	0.011% $ 78.1k
Paul Lizzul	Chief Medical Officer	4.3yrs	US$2.44m	0.051% $ 371.1k
Dennis Mulroy	Chief Financial Officer	4.3yrs	US$1.81m	0.016% $ 114.3k
Beth Mueller	Senior Vice President of Human Resources	5.1yrs	no data	no data
Martin Dahl	Senior Vice President of Research	2.8yrs	no data	no data
Benjamin Stone	Chief Business Officer	less than a year	no data	no data
Douglas Rich	Senior Vice President of CMC	1.8yrs	no data	no data
Monique Da Silva	Senior Vice President of Corporate Affairs	less than a year	no data	no data
Priya Raina	Senior Vice President of Clinical Operations	less than a year	no data	no data
Min Bao	Senior Vice President of Clinical Development	less than a year	no data	no data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Management: 0HFQ's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel Faga	President	3yrs	US$7.46m	1.32% $ 9.7m
John Orwin	Independent Chairman of the Board	1.2yrs	US$338.08k	0.011% $ 80.4k
Hollings Renton	Lead Independent Director	9.4yrs	US$342.38k	0.0064% $ 47.0k
John Schmid	Independent Director	9.4yrs	US$335.38k	0.013% $ 94.0k
Dennis Fenton	Independent Director	6.7yrs	US$331.88k	0.0064% $ 47.0k
Magda Marquet	Independent Director	3.8yrs	US$318.38k	0.013% $ 94.0k
Oleg Nodelman	Independent Director	3.6yrs	no data	no data
J. Ware	Independent Director	7.3yrs	US$338.38k	0.025% $ 180.8k
Rita Jain	Independent Director	1.6yrs	US$495.60k	0.015% $ 109.3k
Dolca Thomas	Member of Scientific Advisory Board	1.8yrs	no data	no data
Luisa Salter-Cid	Member of Scientific Advisory Board	no data	no data	no data
John Monroe	Member of Scientific Advisory Board	no data	no data	no data

3.7yrs

Average Tenure

61yo

Average Age

Experienced Board: 0HFQ's board of directors are considered experienced (3.7 years average tenure).

AnaptysBio Management

Management criteria checks 3/4

Key information

Recent management updates

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Recent updates

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2024 earnings released: US$1.14 loss per share (vs US$1.41 loss in 3Q 2023)

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Second quarter 2024 earnings released: US$1.71 loss per share (vs US$1.50 loss in 2Q 2023)

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings released: US$1.64 loss per share (vs US$1.58 loss in 1Q 2023)

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.57 loss in FY 2022)

No longer forecast to breakeven

No longer forecast to breakeven

High number of new directors

High number of new directors

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.18 loss in 3Q 2022)

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

High number of new directors

High number of new directors

AnaptysBio, Inc. Announces Board Changes

High number of new directors

High number of new directors

Second quarter 2023 earnings released: US$1.50 loss per share (vs US$1.15 loss in 2Q 2022)

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$1.58 loss per share (vs US$1.31 loss in 1Q 2022)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

First quarter 2022 earnings released: US$1.31 loss per share (vs US$0.66 loss in 1Q 2021)

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AnaptysBio, Inc. Announces FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.30 loss in 1Q 2020)

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Full year 2020 earnings released: US$0.73 loss per share (vs US$3.60 loss in FY 2019)

Revenue beats expectations

AnaptysBio, Inc. Announces Board Changes

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age